Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

about

The Pivotal Role of DNA Repair in Infection Mediated-Inflammation and Cancer.Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth

P2860

Q55344660-5727D685-E0F8-4E69-9F31-06B22710597B Q58759078-AA7EBAFB-65FF-4BB3-89D7-C3DD476EC96A

P2860

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

Item

http://www.wikidata.org/entity/Q40323714

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Epstein-Barr virus-specific ad ...... atic nasopharyngeal carcinoma.

@en

type

Item

label

Epstein-Barr virus-specific ad ...... atic nasopharyngeal carcinoma.

@en

prefLabel

Epstein-Barr virus-specific ad ...... atic nasopharyngeal carcinoma.

@en

P1476

Epstein-Barr virus-specific ad ...... atic nasopharyngeal carcinoma.

@en

P2093

Fred C Wang

http://www.w3.org/2001/XMLSchema#string

Heather Daley

http://www.w3.org/2001/XMLSchema#string

Jerome Ritz

http://www.w3.org/2001/XMLSchema#string

Jochen H Lorch

http://www.w3.org/2001/XMLSchema#string

Julian Huang

http://www.w3.org/2001/XMLSchema#string

Lori J Wirth

http://www.w3.org/2001/XMLSchema#string

Mark Fogg

http://www.w3.org/2001/XMLSchema#string

Marshall R Posner

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma.

Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.

Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.

Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

Nasopharyngeal carcinomas: an update.

Pathogenesis and treatment of nasopharyngeal carcinoma.

Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma

Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma.

Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.

P304

2642-2650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30541

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28222215

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

about

P2860

P2860

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921